Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07204275) titled 'A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)' on Sept. 24.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Vertex Pharmaceuticals Incorporated
Condition:
Primary Membranous Nephropathy
Intervention:
Drug: Povetacicept
Recruitment Status: Not recruiting
Phase: Phase 2/Phase 3
Date of First Enrollment: October 6, 2025
Target Sample Size: 17...